Personalis, Inc. (PSNL) - חוב לטווח ארוך להון

The Personalis, Inc. (PSNL) price chart on the GURU.Markets platform reflects a debt-to-equity ratio of 0.14. The business relies on high-precision NGS DNA sequencing to detect disease recurrence while expanding partnerships with pharmaceutical behemoths. The team brings together top bioinformaticians who develop personalized therapy regimens. Due to the precision of its genomic research, the brand is recognized as an authoritative innovator within the medical community.

This indicator determines the share of long-term liabilities within the equity structure, measuring financial leverage and the business's resilience to revenue declines. For Personalis, Inc. (PSNL), which invests in the development of MRD tests and partnerships with pharma behemoths, the long-term debt-to-equity ratio demonstrates the balance between debt-funded expansion and default risk, confirming the company's overall solvency.